Transplantation of progenitor cells which have been mobilised into the bloodstream (PBPC) following the administration of G-CSF results in more rapid neutrophil recovery than transplantation of bone marrow (BM). The reasons for the accelerated neutrophil engraftment are not clear, but would be explained by increased self-replication of myeloid progenitor cells (CFU-GM). We have used a CFU-GM replating assay to investigate myeloid progenitor self-replication, and quantification of subcolony formation during erythroid burst formation to quantify erythroid progenitor selfrenewal. Secondary colony formation by CFU-GM, grown from PBPC and then replated was increased compared with secondary colony formation by BM CFU-GM (P = 0.0001); erythroid subcolony formation was not altered. There was no difference between the replating abilities of PBPC CFU-GM derived from allogeneic donors (normal individuals) and autologous donors (patients with malignant disease) although differences were found between subgroups of autologous donors. The increased replication of PBPC could not be accounted for by a reduction in progenitor cell apoptosis; PBPC CFU-GM contained slightly fewer apoptotic CD34 ؉ cells than BM CFU-GM. The increased replication by PBPC CFU-GM was reversible because it declined when CFU-GM colonies were passaged through three sequential CFU-GM replating cycles. This decline in self-replication was more rapid than the decline seen in replated BM CFU-GM. The self-replication of PBPC CFU-GM, and subcolony formation by BFU-E could be further enhanced by exposure to cytokines in vitro. We conclude that mobilisation alters the replication kinetics of myeloid, but not of erythroid, progenitor cells, that mobilisation-induced events are of limited duration and that in vitro exposure 
Progenitor cells mobilised into the circulation by cytokine exposure 1, 2 or by chemotherapy [3] [4] [5] are a highly accessible resource for autologous or allogeneic stem cell transplantation. Mobilised peripheral blood progenitor cells (PBPC) differ markedly from progenitors derived from bone marrow (NBM) by a range of criteria. In particular, 30-60% of NBM CD34 ϩ cells are in S phase compared with few or none in the PBPC CD34 ϩ population. [6] [7] [8] PBPC CD34
ϩ cells are metabolically inactive, as judged by rhodamine 123 uptake, 9, 10 and show altered surface antigen and adhesion molecule expression compared with NBM CD34 ϩ cells. [11] [12] [13] [14] [15] Functional studies indicate that PBPC cells are enriched for clonogenic cells and for LTC-IC. 8, [16] [17] [18] [19] The relatively extensive changes induced in PBPC by the mobilisation procedure raised concerns initially that the ability of these cells to sustain long-term engraftment might be impaired. 9, 10 In practise, this has not proved to be the case. Moreover, one of the advantages of PBPC transplants is their ability to significantly accelerate white cell recovery immediately post transplant compared with bone marrow. [20] [21] [22] [23] [24] Very few data are available to explain why PBPC are more effective than NBM at initial marrow repopulation. PBPC recipients are infused with greater numbers of granulocyte-macrophage colony-forming cells (CFU-GM) than NBM recipients. However, when PBPC recipients are compared with NBM recipients given the same number of CFU-GM/kg, neutrophil recovery takes 1.52 Ϯ 0.38 times as long in the NBM recipients (20.3 Ϯ 1.98 vs 13.8 Ϯ 2.38 days; P = 0.001). 25 This suggests that qualitative rather than quantitative differences between progenitor cells in bone marrow and mobilised blood are responsible for differences in the speed of neutrophil recovery although it should be noted that some authors [18] [19] [20] have reported a higher proportion of primitive haemopoietic progenitors (LTC-IC) in the PBPC CD34 ϩ population. Scott et al 25 found that mobilised progenitor cells were less sensitive than bone marrow progenitor cells to stromal cell-mediated negative regulation, which might explain the slower neutrophil recovery in BM recipients. Similarly, PBPC CFU-GM were noted to be more responsive than NBM CFU-GM to recombinant cytokine combinations and to have greater productive capacity in vitro. 8 However, Prosper et al 26, 27 found that both the frequency and the in vitro productivity of LTC-IC from NBM and PBPC CD34 ϩ cells were comparable, whilst others showed that the productivities of P⌬ cells (primitive progenitors) and LTCICs from PBPC were reduced. 28, 29 An increase in progenitor cell self-renewal would provide an alternative explanation for rapid neutrophil recovery. [30] [31] [32] We have developed in vitro assays to measure the balance between self-renewal and differentiation of haemopoietic progenitor cells. These are based on secondary colony formation by replated CFU-GM colonies for the myeloid lineage; 33 for the erythroid lineage, the assay is based on subcolony formation during erythroid burst formation. 34 Using these assays, we have demonstrated that selfrenewal in both the erythroid and myeloid progenitor populations varies according to tissue source and is modulated by external factors such as cytokines. [34] [35] [36] Here, we have used the assays to investigate the selfreplicative capacities of mobilised progenitor cells from normal individuals and patients with haematological malignancies. We found that self-replication by mobilised CFU-GM, but not by mobilised BFU-E, was temporarily increased compared to bone marrow. The extent of increased CFU-GM replication varied according to the patients' disease and self-replication by CFU-GM and BFU-E could be (further) increased by exposure to cytokines in vitro. The inference that the superior short-term engraftment of PBPC over BM transplants may be a result of enhanced CFU-GM self-renewal leads to the possibility that stimulation of cells with selected cytokine combinations in vitro prior to transplantation may increase the speed of neutrophil engraftment and have beneficial effects on red cell reconstitution.
Materials and methods

Haemopoietic cell samples
All samples were obtained with informed consent and local research ethics committee approval. G-CSF-mobilised peripheral blood progenitor cell samples were obtained from leukaphereses processed by the Stem Cell Laboratory, Hammersmith Hospital, in excess of clinical requirements. Normal bone marrow was obtained from donations for allogeneic transplantation.
PBSC mobilisation protocols
PBSC were mobilised according to local protocols, using either glycosylated (Lenograstim; Chugai Pharma, London, UK) or non-glycosylated (Filgrastim; Amgen, Welwyn Garden City, UK) G-CSF. G-CSF was used alone at 12 g/kg/day for 5 days to mobilise normal donors for allogeneic transplant or at 10 g/kg/day for 5 days to mobilise myeloma patients for autologous transplant. Other myeloma patients received cyclophosphamide plus 5 g/kg/day G-CSF from day 5. Lymphoma patients were mobilised with etoposide plus 5 g/kg/day G-CSF from day 3 and breast cancer patients with FEC (fluorouracil, epirubicin, cyclophosphamide) plus 5 g/kg/day G-CSF.
CFU-GM assay
Mononuclear cells (MNC) were obtained by density gradient centrifugation over Lymphoprep (Nycomed, Oslo, Norway) and depleted of adherent cells by a 2-h incubation in alpha medium (Gibco, Paisley, UK) plus 15% foetal calf serum in tissue culture plastic flasks at 37°C in 5% CO 2 in air. Non-adherent MNC were plated at 1 ϫ 10 5 /ml in methylcellulose containing serum (Methocult H4230; Metachem Diagnostics, Northampton, UK) and supplemented with recombinant human cytokines (100 ng/ml G-CSF (Granocyte; Chugai Pharma), 1 ng/ml GM-CSF, 5 ng/ml IL3 and 20 ng/ml SCF (First Link, West Midlands, UK)) in petri dishes. For some experiments, cytokine support comprised G-CSF alone or in combination with other factors as defined in the text. The cultures were incubated at 37°C in humidified 5% CO 2 in air for 7 days, and then colonies consisting of at least 50 cells were scored on an inverted microscope.
CFU-GM replating assay
For each sample investigated, 120 consecutive colonies consisting of 50 or more cells after 7 days of culture were visualised under a binocular microscope and plucked from the methylcellulose using a sterile Eppendorf pipette. Each colony was vigorously dispersed in a separate well of a 96-well microtitre plate containing 100 l of methylcellulose plus serum and G-CSF, GM-CSF, IL3 and SCF as previously detailed. The plates were incubated for a further 7 days at 37°C in humidified 5% CO 2 in air. Each well was scored for the presence and number of secondary colonies of 50 or more cells.
CFU-GM sequential replating
CFU-GM were grown for 7 days then 120 colonies picked to determine replating capability, as described above. At the same time, no fewer than 100 colonies of 50 cells or more were plucked from the methylcellulose using a sterile Eppendorf pippette and pooled in 3 ml of fresh methylcellulose culture medium. After vigorous dispersal, three 1 ml aliquots were dispensed into 35 mm 2 petri dishes and incubated in a humidified incubator at 37°C with 5% CO 2 for a further 7 days. After 7 days, 120 individual colonies were again picked to determine AUC and at least 100 colonies were pooled and re-cultured for a further 7 days. The procedure was halted when there were insufficient colonies recovered at day 7 to determine the AUC (see below).
BFU-E assay
Mononuclear cells (MNC) were obtained by density gradient centrifugation over Lymphoprep (Nycomed) and depleted of adherent cells by a 2-h incubation in alpha medium (Gibco) plus 15% foetal calf serum in tissue culture plastic flasks at 37°C in 5% CO 2 in air. Non-adherent MNC were plated at 1 ϫ 10 5 ml in methylcellulose containing serum (Methocult H4230; Metachem Diagnostics) and supplemented with recombinant human cytokines (3 U/ml Epo (Eprex; Jenssen-Cilag, High Wycombe, UK), 25 ng/ml IL3 and 100 ng/ml SCF (both First Link)) in petri dishes. For some experiments, cytokine support comprised Epo alone or in combination with other factors as defined in the text. The cultures were incubated at 37°C in humidified 5% CO 2 in air for 14 days. The cultures were then scored for total BFU-E numbers and the number of sub-colonies determined for at least 120 individual BFU-E.
Data analysis for myeloid or erythroid progenitor selfreplication
The data were analysed using a Microsoft Excel spreadsheet, version 5.0 (Microsoft, Redmond, WA, USA) or a computer program custom-written by Dr NM Blackett. The raw data are the number (n) of secondary CFU-GM produced by each individual primary replated colony or of subcolonies comprising each BFU-E. A cumulative distribution of the proportion of primary CFU-GM producing more than n secondary CFU-GM or BFU-E composed of more than n sub-colonies is plotted on a logarithmic y axis. The x axis is expressed as log 2 n which reflects the number of cell doublings required to produce the observed number of secondary colonies or sub-colonies. This allows the data to be fitted to a logarithmic curve very precisely. Finally, the area-under-the-curve (AUC) is calculated using the trapezium rule. This step is performed because the distribution of secondary colonies per primary CFU-GM and of subcolonies per BFU-E is highly skewed so that median, not mean, values are appropriate. However, in cases where fewer than 50% of the primary colonies yield secondary colonies the median will be zero and not provide any information. The AUC takes account of the proportion of CFU-GM that do not produce any secondary colonies on replating.
Separation of CD34
ϩ cells from day 7 CFU-GM CFU-GM were grown in methylcellulose for 7 days then picked and replated to determine self-replication, as described above. The remaining d7 colonies were pooled into 3 l MM buffer (PBS (Gibco) supplemented with 5 mm EDTA and 0.5% BSA (Gibco)) and mixed vigorously to dissolve the methylcellulose and disperse the cells. The cells were pelleted at 1800 r.p.m. for 5 min. Separation of CD34 ϩ cells was achieved using immunomagnetic beads (MiniMacs; Miltenyi Biotec, Camberley, UK). Briefly, the cell pellet was resuspended in 30 l MM buffer to which was sequentially added 10 l reagent A1 and 10 l reagent A2. After 15 min at 4°C, the cells were washed with 5 ml cold MM buffer and resuspended in 40 l MM buffer. Ten l reagent B was added, incubated at 4°C for a further 15 min then the cells washed in 5 ml MM buffer and resuspended in 1 ml MM buffer. The cells were passed down a pre-flushed column in a magnetic field which was then Bone Marrow Transplantation washed with 4 ϫ 500 l cold MM buffer. After removal from the magnet, CD34 ϩ cells were eluted from the column with 1 ml MM buffer.
Determination of apoptosis by TUNEL in CD34
ϩ cells from CFU-GM
CD34
ϩ cells suspended in MM buffer were mixed with equal volumes of 8% paraformaldehyde for 10 min. The cells were pelleted at 1800 r.p.m. for 5 min then resuspended in Dulbecco's MEM (Gibco) at a concentration of 2 ϫ 10 5 /ml and 100 l volumes cytospun on to cleaned microscope slides at 450 r.p.m. for 10 min (Shandon Cytospin 2; Shandon, Pittsburgh, PA, USA). Slides were airdried overnight, rehydrated in TBS for 15 min at RT and dried. The cells were covered by a 5 ml droplet of protein K diluted 1:100 in 10 mm Tris (pH 8), incubated 5 min at RT then dipped three times into TBS and dried. The specimen was covered with 100 l of the supplied equilibration buffer and incubated for 30 min at RT. Excess buffer was poured off and freshly prepared TdT labelling mixture (3 ml TdT enzyme in 57 ml TdT labelling reaction mix (Frag-EL; Calbiochem, Nottingham, UK)) was layered on to the cells. The slide was incubated at 37°C in a humidified chamber for 1.5 h then washed ϫ 3 in TBS at RT. A coverslip was applied over mounting medium (Frag-EL) and sealed with nail varnish to prevent evaporation. At least 100 cells from randomly selected fields were scored by fluorescent light microscopy (494 nm). Viable cells stained blue whilst apoptotic cells appeared as small fragmented bodies staining bright green.
Statistical analysis
Statistical analysis was performed using StatView SE ϩ graphics software for the Macintosh computer (Abacus Concepts, Berkeley, CA, USA). Figure 1 shows the results obtained in the CFU-GM replating assay from 56 PBPC harvests and 54 normal bone marrow specimens. Overall, the AUC for the PBPC group was markedly and significantly greater than that for the BM group. In contrast, there was no difference between the AUCs derived from PBPC and BM samples in the BFU-E assay (Figure 2 ). These results show that mobilisation increases the capacity of myeloid lineage progenitors to self-replicate, but has no effect on erythroid progenitor cell kinetics.
Results
Self-replication by progenitor cells in PBPC collections
The PBPC group consisted of collections from normal donors for allogeneic transplantation and collections from patients with malignant disease for autografting. The myeloid AUC values for the allogeneic group were 150.3 Ϯ 20.9 (n = 15) and for the autologous group were 186.3 Ϯ 16.5 (n = 38). These values were not significantly different (P = 0.12) (Figure 3) .
Subdivision of the autologous group into collections
Bone Marrow Transplantation from patients with breast cancer, myeloma, non-Hodgkin's lymphoma and 'others' (testicular cancer, germ cell tumour, T cell ALL or Hodgkin's lymphoma) revealed that the myeloid AUC derived from NHL PBPC was significantly lower than that from the allogeneic group (P = 0.026) and that from the rest of the autologous group (P = 0.005), but still greater than the AUC measured from BM (P = 0.01). The AUC from the 'others' was significantly greater than that of the allogeneic group (P = 0.02) and that of the rest of the autologous group (P = 0.05). These results show that self-replication by CFU-GM in allogeneic (normal) and autologous (diseased/treated) PBPC collections is uniformly greater than that of normal marrow CFU-GM. Also, the AUC measured in collections from diseased/treated patients, with the exception of NHL patients, is not lower than that measured for mobilised normal donors, and it may even be higher.
Effects of cryopreservation on CFU-GM self-replication in PBPC harvests
Since the majority of PBPC harvests are cryopreserved before infusion, we tested fresh and frozen-thawed samples from five patients. There was a moderate reduction in AUC from 193 Ϯ 49 in fresh samples to 101 Ϯ 28 in frozenthawed samples (P = 0.005; Wilcoxon signed rank test).
Thus, cryopreservation appears to reduce significantly the ability of surviving CFU-GM to self-replicate.
Increased self-replication by mobilised CFU-GM is not a reflection of reduced apoptosis
The increased number of secondary CFU-GM in PBPCdervied colonies could result from a reduced loss of progenitors by apoptosis during primary colony development. The proportion of apoptotic CD34 ϩ cells in day 7 CFU-GM was measured by Tunel. This gave the apoptosis level in the progenitor population at the time of replating and so relates directly to the AUC subsequently determined. The frequency of apoptotic CD34 ϩ cells was very low in NBMderived colonies (2.2 Ϯ 0.3; mean Ϯ s.e; n = 18) and there was only a small, non-significant reduction in apoptosis in PBPC-derived colonies (1.6 Ϯ 0.4%; n = 17; P = 0.13 (Mann-Whitney U)).
Increased self-replication by mobilised CFU-GM is 'selflimiting'
A sustained increase in myeloid progenitor self-replication could be detrimental and lead to marrow hypercellularity and raised peripheral blood counts. Accordingly, we investigated the replating ability of successive generations of PBPC and BM CFU-GM colonies. The data in Figure 4 show that the replating abilities of PBPC and BM CFU-GM fall exponentially on sequential replating and that the replating ability of PBPC CFU-GM in fact falls faster than that of BM CFU-GM. Thus, the self-replication ability of CFU-GM declines as a function of the number of cell generations.
Cytokine exposure increased self-replication by mobilised myeloid and erythroid progenitors
The above results suggest that in vivo exposure to G-CSF increases the self-replicative capacity of CFU-GM in PBPC collections. We have previously shown that IL-3, but not SCF, increase the replating ability of BM CFU-GM, and subcolony formation by BFU-E, in vitro. 35 To determine whether PBPC CFU-GM and BFU-E respond in a similar fashion we performed the experiments shown in Figures 5  and 6 . The data show that addition of either IL-3 or SCF to G-CSF (CFU-GM) or Epo (BFU-E) significantly increased Statistical comparisons (MannWhitney U) Allogeneic vs autologus P = 0.12 NHL vs allogeneic P = 0.026 vs autologous P = 0.005 vs NBM P = 0.01 Other group vs allogeneic P = 0.02 vs autologous P = 0.05
Figure 3
Self-replication by CFU-GM grown from PBPC collections from different groups of PBPC donors. The donors contributing to the data shown in Figure 1 were first subdivided according to whether they were allogeneic donors (ie normal) or autologous donors (ie diseased/treated). The autologous PBPC group was then subdivided according to the donor's disease. Primary CFU-GM colonies were grown and replated into 96-well plates as before. In addition, batches of primary colonies were replated into petri dishes. Secondary colonies in the petri dishes were replated into 96-well plates (replate number 2). Batches of secondary colonies were also replated into petri dishes. These were subsequently replated into 96-well plates (replate number 3).
the replating ability of progenitors and that even more marked effects are seen when the cytokines are combined.
Discussion
This study has revealed qualitative differences between progenitor cells in PBPC and BM harvests that may account for the more rapid neutrophil recovery observed in recipi-ents of PBPC transplants compared with recipients of BM. The speed of neutrophil recovery following PBPC transplantation suggests that neutrophils are derived from preexisting CFU-GM, rather than from stem cells, in the immediate post-transplant period. However, it may be calculated that 10 8 CFU-GM, or a total nucleated cell dose in the order of of 10 11 would be needed to supply sufficient neutrophils for 1 day. 31 Another possibility is that the CFU-GM have a variable capacity to amplify through selfrenewal that is increased when demand for neutrophils is high. 31 This idea led us to establish the CFU-GM replating assay in order to measure the self-renewal of CFU-GM in various circumstances. 33 The increased replating ability of CFU-GM in PBPC harvests, compared with bone marrow CFU-GM, is therefore consistent with the more rapid rate of neutrophil recovery in recipients of PBPC since whilst a shift in emphasis to self-renewal at progenitor level would briefly reduce the emergence of neutrophils, the amplification potential between CFU-GM and neutrophil is such that even small numerical changes in the progenitor population can have a very large effect on neutrophil output.
Some authorities have proposed that normal steady-state haemopoiesis is accomplished by a considerable loss of progenitor cells by apoptosis. 37 Accordingly, suppression of apoptotic cell loss by, for example, cytokines could provide a mechanism for progenitor cell expansion or recovery. Our results do not, however, support a reduction in apoptotic cell loss as a mechanism for increasing the AUC measured for PBPC-derived CFU-GM colonies. Another explanation for increased AUC in PBPC might relate to prior chemotherapy or periods of cytopenia in the autologous donor group, but there was no significant difference between the total autoPBPC group and the alloPBPC (normal donor group). Thus, the effects we have observed can be attributed to a large extent to the mobilisation treat- 
Figure 6
Effects of IL-3 and stem cell factor (SCF) on sub-colony formation during PBPC erythroid burst formation. Erythroid bursts were grown in Epo to provide baseline data. Significant increases in subcolony formation were seen when IL-3 was added to G-CSF, but not when SCF was added to G-CSF.
ment rather than to treatment with cytotoxic drugs. PBPC from NHL patients did have a significantly lower AUC than either alloPBPC or the rest of the autoPBPC. This might reflect an effect of etoposide as a mobilisation agent. However, the small group of miscellaneous autoPBPC donors categorised as 'others' were also mobilised with etoposide yet had PBPC with an AUC significantly greater than either alloPBPC or the rest of the autoPBPC group, suggesting that the small differences observed are more likely to relate to underlying disease than to mobilisation regime. The AUC of mobilised PBPC, regardless of donor status or mobilisation regime, remained significantly higher than the AUC of NBM progenitors. The sequential replating experiments demonstrated that the self-renewal capability of NBM CFU-GM declines exponentially with serial replating as the progenitor cell population matures with time. The rates of decline are comparable for mobilised PBPC and NBM. The data therefore suggests that the mobilisation procedure induces a temporary elevation in self-renewal from which the cells then decline naturally rather than having a sustained effect which might result in over-production of mature myeloid cells. This is consistent with the data using different cytokines which shows clearly that self-renewal by progenitor cells is very responsive to exogenous control and supports the hypothesis that myeloid homeostasis can be rapidly and reversibly controlled at the progenitor level.
The experiments using the erythroid colony assay showed that the kinetic changes were restricted to the myeloid lineage. This might have been anticipated since mobilisation was accomplished using the myeloid specific growth factor, G-CSF. However, this result does demonstrate that the growth factor itself, and not simply the fact that progenitor cells circulate, may have an important impact on progenitor cell behaviour. The BFU-E population is mobilised into the blood, but BFU-E kinetics are not altered. In conclusion, we have shown that the self-renewal rate of lineage-committed progenitor cells can vary in response to external stimuli such as exogenous cytokines or G-CSF induced mobilisation in vivo. We hypothesise that, in the myeloid series at least, this is a mechanism which allows for rapid increase in the tempo of myelopoiesis without placing proliferative stress on the stem cell compartment. The transient responsiveness of this mechanism to exogenous cytokines, plus the demonstrated superiority of PBPC in short-term engraftment, offer the possibility of artificially enhancing the engraftment capability of progenitor cell infusions prior to transplantation.
